BioSpace News Archive

Hemophilia A, a bleeding disorder that prevents blood from clotting, affects more than 30,000 people in the United States and, in high-risk situations, can lead to death.

Levolta Pharmaceuticals, Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.

Florida Cancer Specialists & Research Institute, LLC (FCS) physicians are presenting the outcomes of 23 clinical trials, the majority being Phase 1, at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting on June 2 – 6 in Chicago, Illinois.

Gemini Bioproducts, LLC, a leading supplier of cell culture reagents and process liquids, a portfolio company of BelHealth Investment Partners, LLC, a Florida-based healthcare private equity firm, announced the opening of a new, state-of-the-art cGMP manufacturing facility and warehouse in West Sacramento, California.

CytomX Therapeutics, Inc. announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Thursday, June 8 at 4:00 p.m. ET.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in fireside chats at the following investor conferences:

Replimune Group, Inc. announced that members from the Replimune management team will present in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 1:00 PM ET at the Marriot Marquis in New York NY.

Cyclerion Therapeutics, Inc. announced that it has received a formal notice from The Nasdaq Stock Market stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550, and that Cyclerion is in compliance with all applicable listing standards.

Alkermes plc announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc, the new independent public company to be established upon the planned separation of Alkermes’ oncology business.

Ocular Therapeutix, Inc. announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 12:30 PM EDT at the Marriott Marquis in New York, NY.